Posted June 2, 2021
Bayer (BAYGn.DE) said on Wednesday it will review the future of its Roundup and other glyphosate-based weedkillers in the U.S. residential market after a judge rejected a $2 billion plan to settle future claims alleging the herbicide causes cancer. The company also said it will reassess its efforts to settle around 30,000 ongoing claims by Roundup users who are alleging they have become sick from the product. Read more.